BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Mirena or Conventional Medical Treatment for Menorrhagia

Completed

Conditions: Menorrhagia

Interventions: Drug: Conventional medical treatment
Drug: Levonorgestrel (Mirena, BAY86-5028)

First Posted Date: 2009-03-18

Last Posted Date: 2015-07-01

Lead Sponsor: Bayer

Target Recruit Count: 647

Registration Number: NCT00864136

International PMS Study - KOGENATE Bayer

Completed

Conditions: Hemophilia A

Interventions: Drug: Kogenate (BAY14-2222)

First Posted Date: 2009-03-18

Last Posted Date: 2009-06-30

Lead Sponsor: Bayer

Target Recruit Count: 200

Registration Number: NCT00864552

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

Phase 3

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Riociguat (BAY63-2521)

First Posted Date: 2009-03-18

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 396

Registration Number: NCT00863681

Locations: 🇵🇹
Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal
🇲🇽
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico
🇲🇽
Pulmocritic, Guadalajara, Jalisco, Mexico

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Phase 3

Completed

Conditions: Non-Small-Cell Lung
Carcinoma

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Placebo

First Posted Date: 2009-03-18

Last Posted Date: 2015-01-19

Lead Sponsor: Bayer

Target Recruit Count: 703

Registration Number: NCT00863746

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Phase 2

Completed

Conditions: Brain Diseases
Spinal Cord Diseases

Interventions: Drug: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
Drug: OptiMARK~0.1 mmol/kg BW

First Posted Date: 2009-03-17

Last Posted Date: 2014-01-13

Lead Sponsor: Bayer

Target Recruit Count: 237

Registration Number: NCT00862459

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 24 locations

Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries

Phase 4

Completed

Conditions: Gene Expression
Cell Proliferation
Wound Healing

Interventions: Drug: Placebo
Drug: Dexpanthenol (BAY81-2996)

First Posted Date: 2009-03-10

Last Posted Date: 2014-12-09

Lead Sponsor: Bayer

Target Recruit Count: 15

Registration Number: NCT00859196

Effect of Riociguat on Bone Metabolism

Phase 1

Completed

Conditions: Pharmacology, Clinical

Interventions: Drug: Placebo
Drug: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg

First Posted Date: 2009-03-04

Last Posted Date: 2016-01-11

Lead Sponsor: Bayer

Target Recruit Count: 17

Registration Number: NCT00855660

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Placebo

First Posted Date: 2009-03-04

Last Posted Date: 2017-08-18

Lead Sponsor: Bayer

Target Recruit Count: 307

Registration Number: NCT00855218

Locations: 🇪🇸
Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain
🇺🇸
Abbott Northwestern Hospital, Minneapolis, Minnesota, United States
🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain

and more 3 locations

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Phase 3

Completed

Conditions: Pulmonary Hypertension

Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo

First Posted Date: 2009-03-04

Last Posted Date: 2023-11-21

Lead Sponsor: Bayer

Target Recruit Count: 262

Registration Number: NCT00855465

Locations: 🇫🇷
Hopital Antoine Beclere, Clamart Cedex, France
🇨🇿
Vseobecna fakultni nemocnice, Praha 2, Czechia

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Completed

Conditions: Bronchitis, Chronic

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-02-19

Last Posted Date: 2012-07-09

Lead Sponsor: Bayer

Target Recruit Count: 2672

Registration Number: NCT00846911

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy